EP2655616A1 - Extraction d'acides nucléiques - Google Patents

Extraction d'acides nucléiques

Info

Publication number
EP2655616A1
EP2655616A1 EP11802388.6A EP11802388A EP2655616A1 EP 2655616 A1 EP2655616 A1 EP 2655616A1 EP 11802388 A EP11802388 A EP 11802388A EP 2655616 A1 EP2655616 A1 EP 2655616A1
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
sample
ion exchange
pvpp
supernatant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11802388.6A
Other languages
German (de)
English (en)
Inventor
Steffen Mergemeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP11802388.6A priority Critical patent/EP2655616A1/fr
Publication of EP2655616A1 publication Critical patent/EP2655616A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase

Definitions

  • the invention relates to a method for extracting nucleic acids by means of a nucleic acid extraction material comprising at least one ion exchange material and PVPP. Furthermore, the invention relates to the use of the extraction material and a kit for nucleic acid extraction.
  • PCR polymerase chain reaction
  • nucleic acids can be amplified very quickly and effectively, and then sequenced or detected.
  • An important application of PCR is clinical diagnostics.
  • the technique is used, inter alia, for the detection of pathogens such as noroviruses.
  • Another field of application is food analysis. For example, it is possible to detect contamination with Salmonella or the presence of allergens in food samples.
  • EP 0 643 140 B1 describes a method for the determination of nucleic acids by detecting the amplification product of the PCR using a dye compound.
  • the dye does not fluoresce in the free state. Only in the reaction with a double-stranded nucleic acid fluorescence can be detected. This makes it possible to determine the type and number of bacteria in a sample.
  • Pathogenic microorganisms detected by means of PCR in food are, for example, Listeria monocytogenes, Campylobacter jejuni and Salmonella.
  • Food contaminated with pathogenic microorganisms causes diseases such as salmonellosis or listeriosis.
  • Regular checks of product batches are necessary to prevent germ-laden foods from entering the market.
  • Conventional microbial salmon // a detection in foods required more than 3 days of long enrichment times.
  • the real-time PCR as By contrast, the sensitive detection method offers the advantage that a result is already known after one day.
  • the analysis of foods such as milk, dairy products and eggs as well as egg products and meat is essential. Furthermore, it is important to detect not only bacteria but also certain viruses in food. Noroviruses are considered to cause acute gastroenteritis.
  • the noroviruses belong to the family of the Calciviridae and are single-stranded, envelope-less RNA viruses which are distributed worldwide.
  • the characteristic clinical picture of acute gastroenteritis includes severe nausea, followed by sudden vomiting and diarrhea, rarely fever. After 12 to 60 hours, the virus is eliminated from the body. Therapy is purely symptomatic and consists of adequate supply of fluid and electrolytes.
  • the noroviruses are excreted via the stool and the vomit.
  • the stool contains a particularly high virus concentration, a dose of less than 100 virus particles is sufficient for an infection.
  • the virus is highly infectious and environmentally stable.
  • the infection is fecal-oral, for example, by hand contact with contaminated surfaces or by oral uptake virus-containing droplets in severe vomiting.
  • the detection of noroviruses can be done on the one hand with an ELISA or on the detection of nucleic acids. Detection with the PCR technique requires a reverse transcriptase. The transcribed RNA is amplified and detected as cDNA (complementary deoxyribonucleic acid). The detection of noroviruses by RT-PCR is much more sensitive and specific than the detection with an ELISA.
  • the purification of nucleic acids on solid phases based on a silica matrix is a technique used in many commercial kits.
  • the principle of purification is based on the binding of the nucleic acids to the solid phase as a function of the pH and of the salt concentration of the buffer. Under chaotropic conditions, the network of hydrogen-bond relationships in the water is disturbed. This repeals the formation of a hydrate shell around the macromolecules (DNA, RNA). In the absence of the chaotropic ions, further Once a hydrate shell out, so that the interaction between silica membrane and macromolecule is repealed.
  • this type of purification was implemented on the one hand in the spin-filter method and on the other hand in the magnetic beads technology.
  • a nucleic acid extraction is disclosed.
  • the extraction takes place in four steps: cell lysis, binding of the nucleic acids to a matrix, and washing and elution of the nucleic acids.
  • the disadvantage here is that the extraction is very time consuming because z. B. numerous washing steps must be performed, in which always nucleic acid is washed out with. This significantly reduces the yield of nucleic acid.
  • this extraction method is difficult to automate.
  • nucleic acids with a silica matrix uses molecules with a large surface area that has a magnetic moment when exposed to a magnetic field.
  • colloidal magnetite Fe 3 O 4
  • colloidal magnetite uses surface-modified porous glasses.
  • These magnetic beads and a special binding buffer are added after lysis of the sample.
  • the nucleic acids bind to the silica matrix.
  • the beads collect on the edge of the vessel and the impurities can be removed in several washing steps.
  • the target molecules dissolve. If a new magnetic field is applied, the elution buffer can be separated from the beads with nucleic acids.
  • the advantage of this technique is the high degree of automation of the work processes with a low expenditure on equipment.
  • EP 1 574 584 B1 describes a method for isolating bacteria from biological samples.
  • the methods are suitable for sample preparation of biological samples for nucleic acid-based or immunodiagnostic detection of bacteria.
  • bacteria are detected and isolated by means of a specific antibody.
  • a disadvantage of the prior art is that also reduces the amount of nucleic acid to be isolated by the numerous purification steps and thus the yield is significantly reduced.
  • the numerous purification steps furthermore lead to the extraction taking a very long time.
  • the methods described in the prior art are difficult or impossible to automate. Furthermore, the extraction can not be performed on all samples.
  • the object of the invention was therefore to provide a nucleic acid extraction which does not have the disadvantages or deficiencies of the prior art.
  • nucleic acid extraction material which does not have the disadvantages of the prior art and comprises at least polyvinylpolypyrrolidone (PVPP) and an ion exchange material.
  • PVPP polyvinylpolypyrrolidone
  • the extraction material according to the invention enables rapid and material-saving extraction or purification of nucleic acids.
  • the extraction material can also be used advantageously for automation processes. In addition, it is universally applicable and does not have to be adapted to individual applications.
  • the ion exchange material is preferably selected from the group comprising Sephadex, Chelex, zeolites and / or Sepharose.
  • Sephadex describes in particular a three-dimensionally crosslinked polysaccharide which is obtained by cross-linking the linear macromolecules of dextran.
  • Sephadex is indifferent to cations and anions and contains many hydroxy groups, making it highly hydrophilic and swelling in water or an electrolyte solution.
  • Sephadex may be conjugated to functional groups comprising diethylaminoethyl, diethyl-2-hydroxypropylaminoethyl, carboxymethyl or sulfopropyl groups.
  • Sephadex is advantageously selected from the group comprising Sephadex G-10, Sephadex G-100, Sephadex G-15, Sephadex G-25, Sephadex G-50 and / or Sephadex G-75.
  • Chelex also refers to a polymer within the meaning of the invention, which preferably binds ions.
  • zeolites are crystalline aluminosilicates.
  • the crystal lattices of the zeolites are in particular composed of Si0 4 and Al0 4 tetrahedra, which are each linked to one another via oxygen bridges and preferably form rings or prisms.
  • SBUs secondary building units
  • zeolites a spatial arrangement of identical cavities, which are accessible via windows (pore openings) or three-dimensional duct systems.
  • Sepharose refers to a modified agarose-based polysaccharide whose polysaccharide chains are linked to form a three-dimensional network.
  • PVPP denotes in particular polyvinylpolypyrrolidones (also crospovidone, derived from cross-linked polyvinylpyrrolidone), which arises in particular when vinylpyrrolidinone is heated with alkalis or divinyl compounds.
  • PVPP is a cross-linked polymer, which is essentially insoluble in water and all solvents.
  • PVPP is advantageously a vinyl monomer copolymer. It may be preferred to use another vinyl monomer copolymer instead of PVPP or in combination with PVPP for a preferred nucleic acid extraction material.
  • a copolymer consisting of vinyl monomers preferably has the general formula on.
  • X is a heteroatom or a pe attached via a heteroatom.
  • Table shows preferred groups:
  • X alkyl (1-alkenes), aryl (for example styrene), OR (vinyl ether), O-CO-R (vinyl ester), COOR (acrylic acid and its ester), CONR 2 (acrylamide ), CN (acrylonitrile), NR 2 (vinylamines), NH-CO-R (vinylamides), S0 3 H (vinylsulfonic acid), PO (OH) 2 (vinylphosphonic acid) and others.
  • the extraction material may advantageously be present as a loose powder, tablet, pellet or chromatography column filler comprising at least one ion exchange material and one PVPP moiety. It is preferred that the loose powder, the tablet, the pellet or the chromatography column filling material contain the ion exchange material and the PVPP fraction in a particle size fraction of 5-1000 ⁇ m, preferably in a range of 50-250 ⁇ m. It was completely surprising that components of samples can be bound by means of the extraction material according to the invention, wherein the nucleic acid to be isolated does not bind.
  • the extraction material is used for sample preparation, in particular for the preparation of samples, preferably nucleic acid samples for PCR analysis.
  • a sample is preferably a culture medium, a body fluid and / or a mixture of material of plant and / or animal origin.
  • nucleic acids can also be extracted from food samples.
  • body fluids z. Stool, saliva, blood, lymph, urine, synovial fluid, digestive juices, secretions, excretions or fluid excretion or other fluids of an organism.
  • the sample may be in liquid or solid form, with a solid form within the meaning of the invention also including frozen samples or tissue or bone samples. includes samples.
  • microorganisms are preferably cultured in a culture medium, the culture medium including all nutrients relevant for microorganisms.
  • the culture medium may be in solid or liquid form and is particularly useful for the culture of microorganisms including bacteria, archaea, fungi, microalgae, protozoa and viruses.
  • RNA refers to an elongated molecule consisting of nucleotides, which has the main function in the cell of converting the genetic information stored in the deoxyribonucleic acid (DNA).
  • mRNA which, as a transcript of the genes, provides the information on protein biosynthesis (translation)
  • rRNA which is available in the form of various species (5S, 16S, 23S in bacteria and 5S, 5,8S, 18S , 28S in higher organisms) is represented in the ribosomes
  • the tRNA which mediates the incorporation of the activated amino acids into the growing protein chain on the ribosomes.
  • RNA molecules can also have enzymatic activities (ribozymes) or take over regulatory function through RNA interference (siRNA, miRNA).
  • siRNA RNA interference
  • miRNA RNA interference
  • RNA viruses the RNA itself carries genetic information. It was completely surprising that RNA comprising mRNA, tRNA, rRNA, snRNA, miRNA, viral RNA or hnRNA can be extracted from a sample by means of a preferred extraction material.
  • DNA can also be isolated from a sample.
  • DNA refers in particular to long-chain polynucleotides which contain the main genetic information (the genome) of the living beings stored therein.
  • the majority of DNA is contained in eukaryotes in the nucleus, in the chromosomes or chromatin. In bacteria, it is not located in a separate cell organelle and usually consists of a single, closed-ring molecule. In addition to the genomic DNA, bacteria contain smaller, likewise ring-shaped DNA molecules, the easily transferable plasmids. It was completely surprising that DNA can be isolated simply and quickly by means of the nucleic acid extraction material. The DNA is in the Essentially not damaged and can be fed as a whole to a subsequent analysis.
  • the invention therefore also encompasses a method for purifying a nucleic acid present in a sample on an analytical or preparative scale, comprising a matrix comprising a. a synthetic or natural ion exchange material and b. a crosslinked polymer having a pyrrolidone structure wherein the sample is contacted with the matrix and, in particular, interacts with the matrix undesirable constituents of the sample comprising proteins, salts, carbohydrates, ions and / or fats.
  • the method for sample preparation for the extraction of nucleic acids from a sample comprises the following steps:
  • nucleic acids from samples, preferably body fluids, plant or animal samples and / or culture media.
  • samples preferably body fluids, plant or animal samples and / or culture media.
  • bacterial or viral nucleic acids from stool samples, nucleic acid-associated nucleic acids from plant or animal samples, and / or nucleic acid from culture media samples.
  • the method can also be carried out fully or partially automatically on a small or large scale.
  • the sample to be examined is brought into contact with a lysis buffer in a first step.
  • lysis refers in particular to the dissolution (lysis) of cells with the assistance of lytic enzymes (lysozymes) and destruction of the cell membranes (cytolysis).
  • lytic enzymes lysozymes
  • cytolysis destruction of the cell membranes
  • the sample be disrupted by mechanical methods such as sonication, French press or glass bead mill.
  • a lysis buffer is preferred since this will damage the nucleic acids less.
  • the lysis buffer in a preferred embodiment comprises a buffer which adjusts a preferred pH range.
  • the lysis buffer is Triton, preferably Triton X-15, X-35, X-45, X-100, X-102, X-104, X-114, X-165, X-305, X-405 and / or X-705.
  • Triton is a nonionic surfactant from the octylphenol ethoxylate group that denatures proteins.
  • Surfactants are amphiphilic (bifunctional) compounds having at least one hydrophobic and one hydrophilic moiety.
  • the hydrophobic radical is usually a possible linear hydrocarbon chain with preferably 8 to 22 carbon atoms.
  • the hydrophilic moiety is either a negatively or positively electrically charged (hydratable) or a neutral polar head group.
  • Surfactant betaines or amino acid surfactants carry negatively and positively charged groups in a molecule.
  • Advantageous properties of the surfactants are the oriented adsorption at interfaces and the aggregation to micelles and the formation of lyotropic phases.
  • Nonionic surfactants have an uncharged, water-solubilizing head group.
  • the buffer to which Triton was added significantly improved the nucleic acid extraction yield.
  • the purified nucleic acid has a high purity, ie it is essentially contaminated by no other ingredients.
  • the purity of the nucleic acid plays an important role in particular in further analysis methods, since numerous enzymes, such as DNA polymerase, are impaired by impurities in their function. This may lead to incorrect results. men.
  • the extraction material of the present invention can be considered as a technical advance, since the nucleic acid is not damaged during extraction and thus represents an optimal starting material for subsequent analyzes. In addition, no further precipitation reactions are necessary to remove further impurities - the extracted nucleic acid can be reused in this form.
  • the mixture of lysis buffer and sample may be preferable to heat or heat the mixture of lysis buffer and sample to ensure complete lysis of the cellular components. It has proven to be extremely advantageous to heat / heat the mixture, preferably stool to 80 ° C to 95 ° C, preferably 90 ° C for 5 minutes to 15 minutes, more preferably for 7 to 10 minutes. At the preferred temperatures, substantially complete denaturation of the proteinogenic components of the sample is achieved, with no damage to the nucleic acid.
  • the sample is preferably centrifuged to form, at room temperature, a Triton phase comprising both undissolved sample constituents and non-polar constituents.
  • an aqueous phase-a supernatant-in which the nucleic acid is present advantageously forms.
  • This supernatant can for example be applied to a centrifuge filter and centrifuged.
  • a preferred filter is, for example, a spin filter.
  • the filter comprises the nucleic acid extraction material, in particular PVPP and an ion exchange material. The nucleic acid permeates the filter and is in solution, with all inhibiting components being bound by the ion exchange material and PVPP and unable to penetrate the filter.
  • the extraction material is in the form of a tablet, pellet or chromatography column filler comprising at least one ion exchange material and one PVPP moiety. It was completely surprising that the extraction material can be carried out as a tablet. This is a easy transport and storage of the extraction material possible.
  • the contacting is carried out so that the supernatant is contacted with a tablet comprising PVPP and ion exchange material and that the mixture thus obtained is again centrifuged and the supernatant is used in particular for a PCR reaction.
  • the tablet After lysing the sample, the tablet can be added to the supernatant. As a result, a rapid extraction of the nucleic acid is possible. It may further be preferred that the lysis buffer and / or ion exchange material be present as a tablet.
  • the lysis buffer in tablet form is added to the sample, whereby the tablet dissolves and lyses the sample.
  • the ion exchange material tablet may be advantageously incorporated into the supernatant with the PVPP.
  • contacting the supernatant with the nucleic acid extraction material is such that the supernatant is applied to a chromatography column comprising the nucleic acid extraction material and that the eluate recovered from the column used in a PCR method.
  • chromatography means, in particular, the physico-chemical separation of substance mixtures on account of their different distribution between a stationary phase and a mobile phase. The individual components are delayed differently as a result of different strong interactions with the stationary phase in relation to the mobile phase; They therefore travel different distances in the same time.
  • Preferred chromatographies are z.
  • Chromatography can provide fast and efficient purification of the sample because the nucleic acid extraction material comprising ion exchange material and PVPP is present in the column as a chromatography column filler. As a result, the purity of the extracted nucleic acid after Chromatgraphie is very high. In essence, any inhibiting or interfering components from the sample can be separated from the nucleic acid by chromatography. The components are preferably retained in the column, with the nucleic acid passing through the column. If only one particular nucleic acid is to be analyzed, digestion can take place by the addition of enzymes.
  • RNA can be digested and separated by DNases.
  • RNA can be digested by RNases if only the DNA is to be analyzed.
  • the extraction material is used for sample preparation, in particular for the preparation of nucleic acid samples for PCR analysis.
  • a PCR preferably includes long-range PCR, nested PCR, inverse PCR, anchored PCR, RT-PCR and quantitative RT-PCR (also real-time PCR).
  • PCR inhibitors are generally divided into three categories: (1) inactivation of the DNA polymerase, (2) degradation of the nucleic acids and (3) the negative influence on the lysis.
  • Inhibitory substances include salts, ions (eg calcium ions), fats or proteins.
  • compounds used for sample preparation also have an inhibiting effect, such as, for example, ethanol or detergents, such as sodium dodecyl sulfate. It was completely surprising that inhibiting components can be easily and quickly separated from the nucleic acid.
  • the nucleic acid does not have to be eluted from a matrix by numerous elution steps, but the components are bound and the nucleic acid is preferably present in a solution.
  • the separation or binding of the constituents which may optionally inhibit a subsequent PCR is effected in particular by two mechanisms.
  • the first mechanism involves the binding of non-polar compounds in an aqueous phase of the sample, in particular by PVPP, which forms a nonaqueous phase under defined conditions.
  • the second mechanism inhibitors of the aqueous phase are removed by separation by molecular weight differences by means of the ion exchange material.
  • a nucleic acid extracted by means of the extraction material can also be characterized by other analysis or quantification methods become.
  • the cut nucleic acid can then be analyzed by gel electrophoresis, for example.
  • the analysis of the extracted nucleic acid by means of microarray methods or other high-throughput screening methods is also preferred.
  • the invention further relates to a nucleic acid extraction kit comprising at least one ion exchange material and PVPP.
  • a nucleic acid extraction kit comprising at least one ion exchange material and PVPP.
  • the kit may also comprise a lysis buffer, in particular in tablet form.
  • the ion exchange material may also be in tablet form.
  • the invention may also be considered as a combination invention.
  • the combination of the known elements ion exchange material and PVPP leads to surprising effects in the extraction of nucleic acids. Only the combination of these compounds leads to synergistic advantages, which bring about an efficient separation of the inhibiting components from the nucleic acids.
  • the constituents bind to the combination of ion exchange material and PVPP, whereby the nucleic acids can not interact with the ion exchange material or PVPP and thus be easily separated from the constituents.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un matériau d'extraction d'acides nucléiques, comprenant au moins un matériau échangeur d'ions et du PVPP.
EP11802388.6A 2010-12-20 2011-12-20 Extraction d'acides nucléiques Withdrawn EP2655616A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11802388.6A EP2655616A1 (fr) 2010-12-20 2011-12-20 Extraction d'acides nucléiques

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10195963A EP2465934A1 (fr) 2010-12-20 2010-12-20 Extraction d'acides nucléiques
EP11802388.6A EP2655616A1 (fr) 2010-12-20 2011-12-20 Extraction d'acides nucléiques
PCT/EP2011/073352 WO2012084909A1 (fr) 2010-12-20 2011-12-20 Extraction d'acides nucléiques

Publications (1)

Publication Number Publication Date
EP2655616A1 true EP2655616A1 (fr) 2013-10-30

Family

ID=43838224

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10195963A Withdrawn EP2465934A1 (fr) 2010-12-20 2010-12-20 Extraction d'acides nucléiques
EP11802388.6A Withdrawn EP2655616A1 (fr) 2010-12-20 2011-12-20 Extraction d'acides nucléiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10195963A Withdrawn EP2465934A1 (fr) 2010-12-20 2010-12-20 Extraction d'acides nucléiques

Country Status (3)

Country Link
US (1) US20130337462A1 (fr)
EP (2) EP2465934A1 (fr)
WO (1) WO2012084909A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011156734A2 (fr) 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Procédé de caractérisation de maladies vasculaires
WO2011156763A1 (fr) 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Méthodes de caractérisation de la fonction rénale
WO2012170037A1 (fr) 2011-06-10 2012-12-13 Hitachi Chemical Co., Ltd. Dispositifs de capture de vésicule et leurs procédés d'utilisation
US20130172208A1 (en) * 2012-01-04 2013-07-04 Hitachi Chemical Research Center, Inc. ASSESSMENT OF BONE MARROW RECOVERY BY MEASURING PLASMA EXOSOME mRNAS
GB201214193D0 (en) * 2012-08-08 2012-09-19 Ge Healthcare Uk Ltd Polymerase chain reaction method for amplifying nucleic acid
DE212013000295U1 (de) 2013-05-06 2016-02-02 Hitachi Chemical Co. America, Ltd. Vorrichtungen zum Einfangen von Zielmolekülen
EP3158085B1 (fr) 2014-06-18 2020-12-02 Clear Gene, Inc. Méthodes pour l'analyse rapide de marqueurs biologiques
US10266895B2 (en) 2014-11-05 2019-04-23 Hitachi Chemical Company Ltd. Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
US10370719B2 (en) 2014-11-12 2019-08-06 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury
JP6624704B2 (ja) 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法
AU2016369603A1 (en) 2015-12-18 2018-07-05 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
CN109619659B (zh) * 2018-12-03 2022-05-13 云南瑞升烟草技术（集团）有限公司 一种烟草核酸提取物在烟草中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670315A (en) 1993-09-13 1997-09-23 Canon Kabushiki Kaisha Nucleic acid determination employing pyryilium dye
US5538870A (en) 1994-09-21 1996-07-23 Boehringer Mannheim Corporation Method for preparing nucleic acids for analysis and kits useful therefor
US6027945A (en) 1997-01-21 2000-02-22 Promega Corporation Methods of isolating biological target materials using silica magnetic particles
EP1574584B1 (fr) 2004-03-10 2006-11-15 Boehringer Mannheim Gmbh Procédé pour isoler des bactéries des échantillons biologiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHANGHYUN ROH ET AL: "Extracting eDNA From Soil and Sludge Samples 97 Comparative Study of Methods for Extraction and Purification of Environmental DNA From Soil and Sludge Samples", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 1 January 2006 (2006-01-01), XP055156056, Retrieved from the Internet <URL:http://rd.springer.com/content/pdf/10.1385/ABAB:134:2:97.pdf> [retrieved on 20141201] *

Also Published As

Publication number Publication date
WO2012084909A1 (fr) 2012-06-28
US20130337462A1 (en) 2013-12-19
EP2465934A1 (fr) 2012-06-20

Similar Documents

Publication Publication Date Title
WO2012084909A1 (fr) Extraction d&#39;acides nucléiques
EP1861495B1 (fr) Utilisation de nucléases pour la décomposition d&#39;acides nucléiques en présence d&#39;agents chaotropes et/ou de tensio-actifs
DE69802191T3 (de) Festphasen-Nukleinsäure-Isolierung
DE60210621T2 (de) Universelle methode und zusammensetzung zur schnellen lysierung von zellen zur freisetzung von nukleinsäuren und ihre detektion
US5010183A (en) Process for purifying DNA and RNA using cationic detergents
DE69730974T2 (de) Verfahren zur isolierung von nukleinsäuren unter anwendung von alkaliner phosphatase
EP1851313B1 (fr) Méthode pour l&#39;isolation d&#39;acides nucléiques dans laquelle les acides nucléiques sont immobilisés à haute température sur une matrice
EP3650454B1 (fr) Procédé d&#39;isolement d&#39;acides nucléiques
DE60129593T2 (de) Zusammensetzungen und verfahren zur extraktion einer nukleinsäure
DE69734263T2 (de) Verfahren zur Isolierung von Ribonucleinsäuren.
EP2501811B1 (fr) Procédé d&#39;enrichissement sélectif et d&#39;isolement de microbes et en outre, optionellement, d&#39;acides nucléiques viraux
DE3639949A1 (de) Verfahren zur trennung von langkettigen nukleinsaeuren
DE10222133A1 (de) Verfahren zur Nukleinsäure-Extraktion und Nukleinsäure-Reinigung
EP1995316A1 (fr) Procédé de purification de cellules préservant lesdites cellules, obtention de cellules et transfection de cellules
WO2009135936A1 (fr) Procédé permettant d’enrichir et d’isoler des biomolécules ou des virus
JP2021520823A (ja) 複雑な試料からの核酸の単離および阻害物質の除去
EP1560926B1 (fr) Nouvelles formulations de tampons pour isoler, purifier et recuperer des acides nucleiques a chaine longue et a chaine courte
EP2010672B1 (fr) Formulations et procédé d&#39;isolement d&#39;acides nucléiques contenus dans des matières premières complexes quelconques et analyse génétique complexe consécutive
DE102011054474B4 (de) System zur Stabilisierung, Aufbewahrung und Lagerung einer Nukleinsäure
DE10033991A1 (de) Verfahren zur Isolierung von Nukleinsäuren
WO2008003776A2 (fr) Procédé permettant d&#39;isoler en parallèle des acides nucléiques à simple brin et à double brin et de retirer de façon sélective des acides nucléiques à double brin d&#39;un mélange d&#39;acides nucléiques à simple brin et à double brin
DE19731670C2 (de) Verfahren zur Reinigung und gegebenenfalls Analyse von Nukleinsäuren aus biologischen Proben
DE60115637T2 (de) Hemmung der denaturierung von nukleinsäureduplexen
DE102010031404A1 (de) Verfahren zur schnellen Bereitstellung von Inhaltsstoffen aus biologischen Proben
WO2022180117A1 (fr) Procédé d&#39;isolement simultané d&#39;acides nucléiques à partir de biomolécules sédimentables et non sédimentables dans des échantillons d&#39;eau

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20141216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150627